Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

New to The Street & Sight & Sound's Visionaries Series Premieres Tomorrow on Bloomberg at 6:30 PM EST, Featuring Acurx Pharmaceuticals NASDAQ:ACXP

NEW YORK CITY, NEW YORK / ACCESS Newswire / March 14, 2025 / The highly anticipated Visionaries Series from New to The Street and Sight & Sound premieres tomorrow on Bloomberg at 6:30 PM EST as sponsored programming, featuring Acurx Pharmaceuticals. This compelling episode follows the incredible journey of co-founders David P. Luci, Robert J. DeLuccia, and Robert G. Shawah - from their college days to building and exiting successful pharmaceutical companies, and ultimately coming together to launch Acurx Pharmaceuticals.

The series explores the vision, perseverance, and expertise that led them to develop groundbreaking antibiotics, addressing urgent global health challenges with innovative treatments.

About New to The Street

New to The Street is a premier televised business program that has been showcasing innovative companies and industry leaders for over 15 years. Airing as sponsored programming on Fox Business, Bloomberg, and major networks, the show provides national TV exposure, earned media coverage, and strategic outdoor advertising. With over 2.4 million YouTube subscribers, New to The Street delivers compelling content that reaches investors, consumers, and business leaders worldwide.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. The company's Gram-positive selective spectrum (GPSS®) technology targets DNA polymerase IIIC (pol IIIC), an essential bacterial enzyme, effectively stopping bacterial replication and leading to cell death.

Acurx's lead product candidate, ibezapolstat, is Phase 3 ready for the treatment of Clostridioides difficile (C. difficile) infection, with international clinical trials set to begin this year. The company is also advancing a novel oral antibiotic for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and developing a parallel program for inhaled anthrax treatment.

Meet the Founding Team: From College to Biotech Success

David P. Luci - Co-Founder, President & CEO

David P. Luci began his career in finance and corporate law, before moving into biotech leadership. He co-founded Acurx Pharmaceuticals after serving as President & CEO of Dipexium Pharmaceuticals (Nasdaq:DPRX), where he successfully led its $69 million merger with PLx Pharma Inc. (Nasdaq:PLXP). With a background in healthcare finance at Ernst & Young LLP and corporate law at Paul Hastings LLP, Mr. Luci has been a driving force in biotech innovation and M&A transactions.

Robert J. DeLuccia - Co-Founder, Executive Chairman

Robert J. DeLuccia's executive leadership and marketing expertise have been instrumental in the growth of multiple pharmaceutical companies. Before co-founding Acurx, he was Executive Chairman of Dipexium Pharmaceuticals, leading it through a successful exit. He previously served as CEO of Immunomedics, Inc., President of Sterling Winthrop, and held senior leadership roles at Pfizer. His strategic vision and business development acumen have helped shape Acurx's long-term success.

Robert G. Shawah, CPA - Co-Founder & Chief Financial Officer

Robert G. Shawah is the financial backbone of Acurx Pharmaceuticals. With over 30 years of experience in finance, accounting, and corporate governance, he previously served as Chief Accounting Officer at Dipexium Pharmaceuticals, helping steer the company through its acquisition. His extensive background in financial management and operations includes leadership roles at Arthur Andersen PC and WR Grace & Co.

A Story of Innovation, Grit, and Success

The Visionaries Series offers a rare glimpse into the founding story of Acurx Pharmaceuticals, from college friendships and early career moves to their breakthroughs in biotech and successful pharma exits. The episode highlights how their combined expertise in finance, corporate strategy, and drug development led to the creation of a company poised to revolutionize antibiotic treatments.

Tune in tomorrow at 6:30 PM EST on Bloomberg to watch this exclusive feature on Acurx Pharmaceuticals, airing as sponsored programming!

SOURCE: New To The Street



View the original press release on ACCESS Newswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.